ETON PHARMACEUTICALS INC (ETON) Stock Price & Overview
NASDAQ:ETON • US29772L1089
The current stock price of ETON is 16.7 USD. Today ETON is down by -0.6%. In the past month the price increased by 13.14%. In the past year, price increased by 7.19%.
ETON Key Statistics
- Market Cap
- 447.894M
- P/E
- N/A
- Fwd P/E
- 18.12
- EPS (TTM)
- -0.12
- Dividend Yield
- N/A
ETON Stock Performance
ETON Stock Chart
ETON Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ETON. When comparing the yearly performance of all stocks, ETON turns out to be only a medium performer in the overall market: it outperformed 50.19% of all stocks.
ETON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ETON. ETON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ETON Earnings
On November 6, 2025 ETON reported an EPS of -0.07 and a revenue of 22.46M. The company missed EPS expectations (-176.25% surprise) and beat revenue expectations (7.55% surprise).
ETON Forecast & Estimates
9 analysts have analysed ETON and the average price target is 30.6 USD. This implies a price increase of 83.23% is expected in the next year compared to the current price of 16.7.
For the next year, analysts expect an EPS growth of 19.86% and a revenue growth 109.09% for ETON
ETON Groups
Sector & Classification
ETON Financial Highlights
Over the last trailing twelve months ETON reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 42.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.39% | ||
| ROE | -28.89% | ||
| Debt/Equity | 1.31 |
ETON Ownership
ETON Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.85 | 934.238B | ||
| JNJ | JOHNSON & JOHNSON | 20.83 | 579.34B | ||
| MRK | MERCK & CO. INC. | 22.63 | 286.278B | ||
| PFE | PFIZER INC | 8.98 | 153.814B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.57 | 122.779B | ||
| ZTS | ZOETIS INC | 17.29 | 51.259B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.87 | 26.195B | ||
| VTRS | VIATRIS INC | 5.67 | 16.304B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.76 | 11.614B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.303B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.501B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.547B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.59 | 4.166B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ETON
Company Profile
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Company Info
ETON PHARMACEUTICALS INC
21925 W Field Pkwy Ste 235
Deer Park ILLINOIS 60010 US
CEO: Sean E. Brynjelsen
Employees: 31
Phone: 18004831140
ETON PHARMACEUTICALS INC / ETON FAQ
What does ETON do?
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Can you provide the latest stock price for ETON PHARMACEUTICALS INC?
The current stock price of ETON is 16.7 USD. The price decreased by -0.6% in the last trading session.
Does ETON stock pay dividends?
ETON does not pay a dividend.
What is the ChartMill rating of ETON PHARMACEUTICALS INC stock?
ETON has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists ETON stock?
ETON stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of ETON PHARMACEUTICALS INC (ETON)?
ETON PHARMACEUTICALS INC (ETON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).